Valneva SE operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Valneva SE with three other
pharmaceutical manufacturers in Europe:
Dottikon ES Holding AG
sales of 121.43 million Swiss Francs [US$125.71 million]
of which 90%
was Pharma Products),
Advanced Medical Solutions Group plc
of the United Kingdom
(£82.62 million [US$114.28 million]
of which 39%
was OEM), and
based in Romania
(420.00 million Romanian Leu [US$110.12 million]
During the year ended December of 2016, sales at
Valneva SE were 94.06 million Euro (US$114.57 million).
increase of 20.0%
versus 2015, when the company's sales were 78.36 million Euro.
This was the fourth straight year of sales growth at Valneva SE.
Sales of Commercialized Vaccines saw an increase
30.2% in 2016, from
62.05 million Euro to 80.82 million Euro.
Not all segments of Valneva SE experienced an increase in sales in 2016:
sales of Technologies and Services fell 44.5% to 6.99 million Euro.